作者
Theresa M Visarius, Heinz Bähler, Adrian Küpfer, Thomas Cerny, Bernhard H Lauterburg
发表日期
1998/3/1
期刊
Drug Metabolism and Disposition
卷号
26
期号
3
页码范围
193-196
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Thiodiglycolic acid has been identified as a major metabolite of the anticancer drug ifosfamide in humans. Patients treated with 12–16 g ifosfamide/m2·day excreted thiodiglycolic acid ranging from 0.10 ± 0.02 mmol on the first day of therapy, to a maximum of 3.27 ± 0.15 mmol on the fourth day of ifosfamide infusion. This amounted to 5.4 ± 0.2% of the administered dose of ifosfamide appearing as thiodiglycolic acid in urine during a 5 days’ continuous ifosfamide infusion. Thiodiglycolic acid (50mg/kg) administered to rats inhibited the carnitine-dependent oxidation of [1-14C]palmitic acid by 55%, but affected neither the oxidation of [1-14C]octanoic acid, which is carnitine-independent, nor the oxidation of [1,4-14C]succinic acid, a marker of Kreb’s cycle activity. Additionally, thiodiglycolic acid (30μM) inhibited oxidation of palmitic acid but not palmitoyl-L-carnitine in isolated rat liver mitochondria, indicating that it either …
引用总数
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023212332442345222121111
学术搜索中的文章
RB VAN BREEMEN, D NIKOLIC, JL BOLTON - DRUG METABOLISM AND DISPOSITION, 1998